High Throughput Screening of Nanomaterials: The Arkansas Research Consortium in Nanotoxicity, a partnership between Arkansas and the FDA

摘要

Arkansas and the FDA have executed a Memorandum of Understanding with the US Food and Drug Administration to establish the Arkansas Research Consortium in Nanotoxicity (ARCN) as a collaboration between state universities and the FDA National Center of Toxicological Research in Jefferson, AR. This research effort is coordinated by the Arkansas Research Alliance and directed by a scientists with expertise in synthesis, characterization, detection and toxicity testing in in vitro, in vivo and environmental models. Research projects are distributed in laboratories at 5 state Universities, the University of Arkansas, University of Arkansas at Pine Bluff, University of Arkansas at Little Rock, the University of Arkansas for Medical Sciences and Arkansas State University. This group has selected carbon-based graphenes as a model for developing high-throughput, rapid screening procedures that are broadly applicable to a variety of existing and yet-to-be developed nanomaterials.